Want to see AU:IMC full AI Analyst Report?
Top Page
Immuron Limited
(Sydney:IMC)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.05
▲(35.00% Upside)
Action:Reiterated
Date:09/08/26
The score is held back primarily by weak financial sustainability—persistent operating losses and ongoing negative operating/free cash flow—despite strong gross margins and improving revenue scale. Technicals are a key offset, with the stock trading above major moving averages and showing constructive (not overextended) momentum. Valuation remains constrained by negative earnings and no dividend yield support.
Positive Factors
Revenue Scale and Growth
Revenue has scaled meaningfully over several years, indicating improving commercial traction for Immuron’s marketed products and platform. Continued top-line expansion can broaden operating leverage, support investment in development, and strengthen the company’s ability to build a durable commercial presence.
Negative Factors
Persistent Operating Losses
Immuron has not yet demonstrated sustained earnings despite revenue growth and strong gross margins. Persistent operating losses show that the current cost base remains well above commercial revenue, making the company’s path to self-sustaining profitability dependent on further scale or expense improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale and Growth
Revenue has scaled meaningfully over several years, indicating improving commercial traction for Immuron’s marketed products and platform. Continued top-line expansion can broaden operating leverage, support investment in development, and strengthen the company’s ability to build a durable commercial presence.
Read all positive factors
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$12.91M
Dividend YieldN/A
Average Volume (3M)71.26K
Price to Earnings (P/E)―
Beta (1Y)0.44
Revenue Growth5.85%
EPS Growth42.92%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding322,848,080
10 Day Avg. Volume142,004
30 Day Avg. Volume71,258
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.89
Price to Sales (P/S)1.27
P/FCF Ratio-3.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$8.98M
Immuron Limited Business Overview & Revenue Model
Company Description
Immuron Limited, an Australian biopharmaceutical firm founded in 1994 and headquartered in Carlton, is dedicated to the exploration, advancement, and worldwide commercialization of polyclonal antibodies. Operating across two divisions—Research and...
How the Company Makes Money
Immuron makes money primarily through the sale of its commercial products and, to the extent applicable, through collaborative/partnering arrangements tied to development and commercialization of its candidates.
Key revenue streams include:
1) Pr...
Immuron Limited Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
58
Neutral
Cash Flow
32
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.71M | 7.29M | 4.90M | 1.80M | 765.19K |
| Gross Profit | 4.98M | 4.77M | 3.34M | 1.31M | 523.50K |
| EBITDA | -4.74M | -5.31M | -6.19M | -3.80M | -3.08M |
| Net Income | -3.84M | -5.22M | -6.94M | -3.79M | -2.85M |
Balance Sheet | |||||
| Total Assets | 12.99M | 10.13M | 15.55M | 21.99M | 24.86M |
| Cash, Cash Equivalents and Short-Term Investments | 9.02M | 5.87M | 11.66M | 18.99M | 22.11M |
| Total Debt | 0.00 | 117.13K | 173.50K | 189.09K | 209.79K |
| Total Liabilities | 1.99M | 2.06M | 2.84M | 2.37M | 1.68M |
| Stockholders Equity | 11.01M | 8.07M | 12.71M | 19.62M | 23.18M |
Cash Flow | |||||
| Free Cash Flow | -3.07M | -6.14M | -5.56M | -2.50M | -3.14M |
| Operating Cash Flow | -3.07M | -6.14M | -5.56M | -2.49M | -3.13M |
| Investing Cash Flow | 3.03M | -2.90M | 327.56K | -2.74M | 11.74K |
| Financing Cash Flow | 6.49M | 199.75K | 829.00 | -35.02K | -36.26K |
Immuron Limited Technical Analysis
Positive
0.04
Price Trends
0.04
Positive
0.04
Positive
0.04
Positive
Market Momentum
<0.01
Negative
56.58
Neutral
45.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMC, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.04, and above the 200-day MA of 0.04, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.58 is Neutral, neither overbought nor oversold. The STOCH value of 45.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:IMC.
Immuron Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$80.94M | 22.05 | 46.74% | ― | 29.68% | 1520.00% | |
54 Neutral | AU$81.14M | -14.00 | -211.39% | ― | -46.59% | 9.09% | |
52 Neutral | AU$23.12M | -16.98 | -29.22% | ― | ― | 81.00% | |
52 Neutral | AU$23.52M | -4.42 | -20.36% | 8.28% | -30.79% | -177.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$12.91M | -3.10 | -31.88% | ― | 5.85% | 42.92% | |
44 Neutral | AU$3.16M | -2.94 | -101.34% | ― | ― | 64.58% |
* Healthcare Sector Average
AU:IMC
Immuron Limited
0.05
-0.02
-22.86%
AU:AVE
Avecho Biotechnology Limited
0.02
<0.01
90.00%
AU:ANR
Anatara Lifesciences Ltd
0.01
0.00
0.00%
AU:AGN
Argenica Therapeutics Ltd
0.18
-0.08
-30.00%
AU:EZZ
EZZ Life Science Holdings Ltd.
0.49
-1.68
-77.56%
AU:BIO
Biome Australia Ltd
0.36
-0.13
-25.77%
Immuron Limited Corporate Events
Immuron to Launch Calmino’s Digestive Health Device PROIBS in U.S. Market
Sep 3, 2026
Immuron Limited has signed an exclusive U.S. distribution agreement with Sweden’s Calmino group AB to launch PROIBS®, a European-certified medical device for abdominal pain, bloating and irregular bowel movements, following its introduc...
Immuron Issues FY26 Preliminary Results With Safe Harbor Caution
Aug 27, 2026
Immuron Limited has released preliminary financial results for fiscal year 2026 for its listings on Nasdaq and the ASX, noting that these figures remain subject to audit review. The company also cautions that statements in the presentation are for...
Immuron Narrows Loss as Travelan Sales Lift Revenue and Cash Reserves
Aug 27, 2026
Immuron Limited reported a 5.9% rise in revenue to $7.7 million for the year ended 30 June 2026, driven mainly by higher Travelan sales in Australia and North America, while its net loss narrowed 26.4% to $3.8 million as research and development s...
Immuron CEO to Spotlight Oral Immunotherapy Portfolio at Emerging Growth Conference
Aug 18, 2026
Immuron’s chief executive officer, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, highlighting the company’s strategy and its suite of oral immunotherapy products. The appearance undersc...
Immuron CEO Showcases Gut-Targeted Antibody Platform at TechKnow Invest Roadshow
Jul 26, 2026
Immuron CEO Steven Lydeamore is presenting today at the TechKnow Invest Roadshow in Melbourne, highlighting the company’s orally delivered polyclonal antibody platform and commercial portfolio. The appearance underscores Immuron’s focu...
Immuron Seeks Transformational Partnership for C. difficile Drug IMM-529
Jul 5, 2026
Immuron Limited has engaged life sciences advisory firm Pullan Consulting to secure a strategic partner for its Clostridioides difficile infection candidate IMM-529, which holds U.S. FDA Investigational New Drug approval for a Phase 2 trial. The m...
Immuron Adjusts Capital Structure as Over 3.8 Million Shares Cease
Jun 29, 2026
Immuron Limited has notified the market of the cessation of 3,805,528 ordinary fully paid shares, as disclosed in an Appendix 3H filing to the ASX. The cessation of these securities alters the company’s issued capital structure, which may af...
Immuron Options Lapse, Trimming Potential Dilution in Capital Structure
Jun 18, 2026
Immuron Limited has notified the market that 1,430,000 listed options, identified under the ASX code IMCAI and carrying various expiry dates and exercise prices, have lapsed unexercised. The expiry of these options reduces the company’s outs...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.